Sign In
Buy AVDL
$21.64
+0 (+0%)
At Close: May 08, 2026
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz
10:41am, Friday, 18'th Oct 2024
The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy.
US FDA expands approval for Avadel's sleep disorder drug
10:03am, Thursday, 17'th Oct 2024
The U.S. Food and Drug Administration has approved Avadel Pharmaceuticals' sleep disorder drug for children aged 7 years and older, broadening its use and heating up competition for widely used treatm
-- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy—
– Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ over twice-nightly oxybate regimens –
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
08:00am, Wednesday, 28'th Aug 2024
DUBLIN, Ireland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that mem
Avadel Pharmaceuticals plc (AVDL) Q2 2024 Earnings Call Transcript
12:27pm, Friday, 09'th Aug 2024
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Austin Murtagh - Director, Precision AQ Greg Divis - Chief Executive Officer R
Does Avadel (AVDL) Have the Potential to Rally 43.6% as Wall Street Analysts Expect?
11:01am, Monday, 05'th Aug 2024
The mean of analysts' price targets for Avadel (AVDL) points to a 43.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Avadel Pharmaceuticals to Join Russell 3000® Index
04:05pm, Thursday, 27'th Jun 2024
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
08:00am, Thursday, 30'th May 2024
DUBLIN, May 30, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of ma
Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
08:00am, Wednesday, 22'nd May 2024
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ –
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
07:00am, Tuesday, 21'st May 2024
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appoi
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results
07:00am, Wednesday, 08'th May 2024
-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel's RYZUP patient support services and more than 1,700 patients i
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
08:00am, Wednesday, 01'st May 2024
DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it w
Wall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should Know
10:56am, Monday, 29'th Apr 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positiv
Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
03:40am, Tuesday, 02'nd Apr 2024
Avadel Pharmaceuticals reports strong Q4 2023 earnings for Lumryz, its once-nightly formulation of sodium oxybate for narcolepsy. Lumryz fills a significant gap in narcolepsy treatment by offering a m
